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Mortality in hereditary antithrombin-lll
def iciency—1830 to 1989
F. R. ROSENDAAL H. HEIJBOER E. BRIET H. R. BÜLLER
D. P. M. BRANDJES K. DE BRUIN D. W. HOMMES
J. P. VANDENBROUCKE
To determine whether antithrombin-lll (AT-III)
deficiency leads to an excess mortality, we studied
171 individuals from ten families with a proven
hereditary deficiency. 73 were classified äs certainly
deficient either by direct measurement of AT-III
concentration or by mendelian inheritance patterns.
98 individuals had a high probability (05) of
deficiency. The 64 deaths recorded did not exceed
those expected for the general population adjusted
for age, sex, and calendar period. We suggest that a
policy of prophylactic anticoagulation for patients
with AT-III deficiency cannot be recommended.
Lancet 1991, 337: 260-62
Introduction
Hereditary antithrombin-III (AT-III) deficiency is an
uncommon autosomal disorder that is associated with a
tendency to venous thromboembolism in hcterozygous
individuals.1·2 The severity of venous thrombosis ranges
from superficial thrombophlebitis to pulmonary embolism
but the risk of severe thromboembolism in AT-III deficient
individuals is largely unknown.
The decision to anticoagulate symptom-free AT-III
deficient individuals prophylactically is therefore difficult
and a randomised trial of anticoagulant treatment against
placebo is unfeasible since the disorder is rare and a long
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follow-up would be required to give a definitive answer.
Furthermore, die risks of long-term anticoagulant
treatment are substantial.3
To study the natural history of AT-III deficiency, we
compared mortality in AT-III deficient families with that of
the general population. If the mortality were lower in the
general population, one could estimate the potentially
beneficial effect of anticoagulant treatment.
Subjects and methods
Study population
All Durch farruhes, with a member known to be AT-111 deficient
and who was under the care of the Departments of Haematology of
the Umversity Hospitals of either Leiden or Amsterdam, were
ehgible for study Diagnosis was based on AT-III anugen
concentrations less than 75% of normal, in the absence of hepann
treatment, chronic hver disease, or nephrotic syndrome Only
families with 2 or more deficient individuals were studied, to avoid
inclusion of patients with an acquired deficiency Furthermore, we
included only families with at least one symptomauc defiaent
individual
In all families, non-deficient individuals were excluded and ior
untested family members iniormation from relatives was used to
assign a probabihty of deficiency Since Α'Γ-III deficiency is an
autosomal disorder, some untested individuals can be taken äs
hetero/ygous for Α'Γ-III deficiency—these family members have
passed on the affected gene from common ancestors to deficient
individuals. Mendehan probabihties can be assigned to all
individuals in a pedigree We restriaed our study population to
those who were deficient with certainty or had a probabihty of
deficiency of 0 5 We re)ected the possibility of recent mutations,
which may theoretically have taken place in smaller pedigrees,
because of the Iow frequency of AT-III deficiency. This method
requires complete pedigrees. Since 1809 it has been mandatory by
law in the Netherlands to report all births and deaths to the
municipal registnes All Information in this study has been venfied
by reference to these municipal and national registnes
Analysis
The mortality of the study population (observed) was compared
with the general population adjusted for age, sex, and calendar
penod (expected) The ratio of observed to expected number of
deaths (O E) is the standardised mortality ratio (SMR) The
expected mortality is denved by multiplying the total number of
vears hved by the study population in each calendar penod, and for
each age and sex category, by the mortality rates (age and sex
specitlc) of the general population for each calendar penod
Qmfidence limits for the SMR are based on a Poisson distnbution
for the observed number of deaths 4
Calendar periods were divided into twenty-year intervals from
1830 to 1989, and to each of these we applied the population
mortality rates of the mid-interval year, from 1840 onwards. In each
calendar period we subdivided by sex and age class (0-1 yr, 1-4 yrs,
5-9 yrs, and beyond in five-year age groups). Population mortality
rates were obtained from the Central Bureau of Statistics. To
eliminate bias that may have led to a spuriously low SMR, we
ignored the first two decades of life, both for observed and expected
mortality, the explanation being that those who passed on the gene
to their descendents had to live until reproductive age before they
could do so. This reason did not apply for those assigned a 0-5
probability of deficiency. In addition, we analysed mortality by age.
Results
We identified ten families with 2 or more AT-III-
deficient individuals and at least one symptomatic deficient
individual. The cutoff concentration for AT-III antigen of
75% of normal was satisfactory because all measurements
were either less than 69% (taken äs deficient) or greater than
83% (normal). 73 classified äs deficient with certainry: 23
based on Information on family members (in 16 confirmed
by AT-III measurement) and 50 based on low AT-III
plasma concentrations. In addition, 98 individuals had a 0-5
probability of deficiency. No subject was lost to follow-up.
The smallest farnily contributed 6 subjects to the study
group, and the largest, 39. Three to six generations were
represented in these families. Birth year and year of death
ranged from 1830 to 1989 and 1899 to 1987, respectively.
Of a total of 8168 person-years (all ages combined), 64
deaths took place. Therc were 5066 person-years in the over
20 age group and 56 deaths. 65% of those who died were
bom before 1900, while 55% died before 1950. Mean age of
death was 57 years, median 66 yr). The mortality in the
study group did not differ from that of the general
population. The expected number of deaths was 58-8 (aged
20 years and older). The relative mortality was l Ό (O/E,
56/58-8; SMR, 1-0; 95% confidence interval, 07-1-2). In
the group classified äs deficient with certainty there was no
excess mortality: 9 deaths took place compared with 98
deaths expected (SMR, 0-9; 95% CI, 0-4-1-6). Subjects
with a 0-5 probability of deficiency also had a mortality
frequency comparable with the general population (O/E,
47/48-9; SMR, l -0; 95% CI,0-7-1 -3). For men > 20 yrs, the
SMR was 0-9 (O/E, 36/41 9; 95% CI, 06-12), and in
women the SMR was l -2 (O/E, 20/16-9; 95% CI, 07-1 -8).
In addition, although a deficiency of AT-III may increase
risk of postpartum thrombosis, there was no excess
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Fig 17Mortality in AT-III deficiency by calendar period
monality in womcn aged 20-40 yrs (O/E, 3/2-5; SMR, 1-2;
95% CI, 0-2-3-0).
Figure l shows the relative mortality for different
calendar periods from 1830 to the present. Although some
Variation exists, AT-111 deficiency does not appear to lead to
excess mortality. Figure 2 shows the mortality ratio for
different age groups and includes those subjects aged ^19.
In this young group, relative mortality is low (O/E, 8/27-5;
SMR, 03). This may be because of preferential inclusion of
those who had children or under-reporting of child deaths in
the nineteenth Century. In all other age groups observed
mortality was equal to expected mortality.
Discussion
We studied the natural history and mortality of AT-III
deficiency since most individuals in our study group lived
before anticoagulant therapy became available. No excess
monality was found and confidence intervals were narrow.
In any genetic study there is a risk of bias and although the
frequency of AT-III deficiency in the general population is
low, the recruitment of affected family members was
probably incomplete because not every individual will
manifest venous thromboembolism. Incomplete data
collection will lead to a biased estimate only if ΑΤ-ΙΙΓ
deficiency runs a different course in different families and
breeds true within those families. Severely affected families
are then more likely to be included than mildly affected
families.and so mortality may be overestimated. Since no
excess mortality was found, this possibility is unlikely. Part
of the study group only had a probability of being deficient
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Fig 2—Mortality in AT-III deficiency by age
in AT-III and therefore some individuals may, in reality,
have had normal AT-III concentrations. However, we
found no excess mortality in the subgroup of individuals
proven to be deficient. The inclusion of individuals with a
0-5 probability of deficiency allowed us to both increase the
statistical power of the analysis by extending the study back
to 1830 and reduce bias by selecting those who reproduced
or were tested.
Life-long anticoagulant treatment is probably indicated
after a first episode of thromboembolism.56 The need for
long-term prophylaxis with anticoagulants in symptom-free
AT-III deficient individuals is uncertain.7 Some groups
recommend life-long prophylaxis in all deficient
individuals,5 while others argue that anticoagulation should
be reserved for those with additional risk factors for or a
previous history of thromboembolism.6^8 Until now,
evidence has been confmed to case reports. Our study, in
complete family pedigrees, suggests that life-long treatment
with anticoagulants in symptom-free AT-III deficient
individuals is unlikely to improve survival.
We thank members of all families in this study who kindly provided us with
Information and Mrs W. M. P. Noteboom for her diligence and perseverance
in the genealogical research.
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